BioEP

BioEP is a seizure susceptibility assessment technology that can provide objective support to clinicians enabling faster and more accurate diagnosis and prognosis of epilepsy.

Epilepsy is a serious neurological condition that impacts over 65M people around the world.

BioEP is a patented seizure risk score calculated from routine EEG recordings that can enable faster and more accurate diagnosis and prognosis of epilepsy.

Neuronostics is a collaborative organisation and welcomes enquiries from researchers, clinicians and commercial partners.

We are Neuronostics

Neuronostics is a fast growing med-tech company, passionate about using research to improve the lives of people with epilepsy.

We are developing a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP.

Our goal at Neuronostics is to improve the quality of life of people with epilepsy, those suspected of having epilepsy and those family and friends who share their lives with them.

We are working in partnership with members of the public, people with epilepsy, special interest groups, researchers, doctors and neurologists, to bring the benefits of #BioEP to the wider community globally.

LATEST NEWS
Find out the latest news and information from Neuronostics.

We’re looking for an administrator!

Following on from our recent funding, we’re currently advertising for a part-time administrator to join Neuronostics. It’s a brand new role for the company, and will support lots of activities – helping... [Read More]

Neuronostics close oversubscribed seed funding round

26 March 2021 We’re delighted to announce that we have successfully secured £300K for the ongoing development of our revolutionary clinical decision support systems. The funds being received from a group of... [Read More]

ConnectEP wins innovation award

23 March 2021 We were delighted to receive the Innovation award last night at the MedilinkSW awards. Having won the regional and national start-up award from Medilink UK last year, we were... [Read More]